MEDICINOVA INC
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
MNOV$1.40-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common stock · Additionalpaid-in · Accumulatedothercomprehensive · Accumulated · Totalstockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | capital | loss | deficit | equity | |
| Balance at December 31, 2023 | 49,046,246 | $49,046 | $478,149,161 | $(118,090) | $(415,701,693) | $62,378,424 |
| Stock-based compensation | — | — | 1,191,740 | — | — | 1,191,740 |
| Net loss | — | — | — | — | (11,049,549) | (11,049,549) |
| Foreign currency translation adjustments | — | — | — | (17,064) | — | (17,064) |
| Balance at December 31, 2024 | 49,046,246 | 49,046 | 479,340,901 | (135,154) | (426,751,242) | 52,503,551 |
| Stock-based compensation | — | — | 829,095 | — | — | 829,095 |
| Issuance of common stock under standby equity purchase agreement (SEPA) | 175,000 | 175 | 243,843 | — | — | 244,018 |
| Net loss | — | — | — | — | (11,997,957) | (11,997,957) |
| Foreign currency translation adjustments | — | — | — | 7,974 | — | 7,974 |
| Balance at December 31, 2025 | 49,221,246 | $49,221 | $480,413,839 | $(127,180) | $(438,749,199) | $41,586,681 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.